Pharmacokinetic, Safety and Tolerability Study of SPARC1028
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sun Pharmaceutical Industries
- 20 Oct 2016 Status changed from active, no longer recruiting to completed.
- 30 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016.
- 15 Dec 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.